Researching the research

REBIF (interferon beta-1a) and AVONEX (interferon beta-1a) are currently used for the treatment of Australians living with relapsing forms of MS. Recently, there were some changes announced to their listing on the PBS.

From 1 April 2023, AVONEX will no longer be available on the Pharmaceutical Benefits Scheme (PBS) for Australians living with MS.